EUVIMEDEUVIMED entdecken
Open Access

Mineralocorticoid Receptor in Endothelial Cells Contributes to Vascular Endothelial Growth Factor Receptor Inhibitor-Induced Vascular and Kidney Damage

Nicholas D Camarda iD, Qing Lu, Angelina F Tesfu, Rui R Liu, Jaime Ibarrola, Iris Z Jaffe

American Journal of Hypertension · 2025

DOI: 10.1093/ajh/hpae140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hypertension, 2025. Verfasst von Nicholas D Camarda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Receptors, Mineralocorticoid, Endothelial Cells, Receptors, Vascular Endothelial Growth Factor, Hypertension. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, NHLBI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Vascular endothelial growth factor receptor inhibitors (VEGFRis) improve cancer patient survival by inhibiting tumor angiogenesis. However, VEGFRis induce treatment-limiting hypertension which has been associated with impaired vascular endothelial cell (EC) function and kidney damage. The mineralocorticoid receptor (MR) regulates blood pressure (BP) via its effects on the vasculature and the kidney. Thus, we interrogated the role of the MR in EC dysfunction, renal impairment, and hypertension in a mouse model of VEGFRi-induced hypertension using sorafenib. METHODS EC dysfunction in mesenteric arterioles was assessed by immunoblotting for phosphorylation of endothelial nitric oxide synthase (eNOS) at serine 1177. Renal damage was measured by assessing glomerular endotheliosis histologically. BP was measured using implanted radiotelemetry. RESULTS Six days of sorafenib treatment significantly impaired mesenteric resistance vessel EC function, induced renal damage, and increased BP. Pharmacologic MR blockade with spironolactone prevented the sorafenib-induced decline in eNOS phosphorylation and renal glomerular endotheliosis, without affecting systolic BP (SBP) or diastolic BP. Mice with the MR knocked out specifically in ECs (EC-MR-KO) were protected from sorafenib-induced EC dysfunction and glomerular endotheliosis, whereas smooth muscle cell-specific MR (SMC-MR) knockout mice were not. Neither EC-MR nor SMC-MR knockout affected the degree to which sorafenib increased SBP or diastolic BP. CONCLUSIONS These results reveal that the MR, specifically in EC but not in SMCs, is necessary for VEGFRi-induced renal and vascular injury. While ineffective at lowering SBP, these data suggest potential therapeutic benefits of MR antagonists, like spironolactone, to protect the vasculature and the kidneys from VEGFRi-induced injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, MineralocorticoidEndothelial CellsReceptors, Vascular Endothelial Growth FactorHypertensionProtein Kinase InhibitorsKidneyAnimalsSorafenibMineralocorticoid Receptor AntagonistsNitric Oxide Synthase Type IIIMaleDisease Models, AnimalMice, Inbred C57BLMiceBlood PressurePhosphorylationSpironolactoneMice, Knockout

Stichwörter der Autor:innen

blood pressureendothelial dysfunctionhypertensionmineralocorticoid receptorrenal dysfunctionvascular endothelial growth factor receptor inhibitor

Substanzen

SorafenibReceptors, MineralocorticoidMineralocorticoid Receptor AntagonistsNitric Oxide Synthase Type IIIReceptors, Vascular Endothelial Growth FactorNos3 protein, mouseProtein Kinase InhibitorsSpironolactone

Autor:innen und Institutionen

  • Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA.
  • Genetics, Molecular, and Cellular Biology Program, Tufts Graduate School of Biomedical Sciences, Boston, Massachusetts, USA.

ORCID-Profile: Nicholas D Camarda

Förderung

  • NHLBI NIH HHS
  • NIGMS NIH HHS
  • NHLBI

Zitieren

APA

Camarda, N. D., Lu, Q., Tesfu, A. F., Liu, R. R., Ibarrola, J., & Jaffe, I. Z. (2025). Mineralocorticoid Receptor in Endothelial Cells Contributes to Vascular Endothelial Growth Factor Receptor Inhibitor-Induced Vascular and Kidney Damage. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpae140

Vancouver

Camarda ND, Lu Q, Tesfu AF, Liu RR, Ibarrola J, Jaffe IZ. Mineralocorticoid Receptor in Endothelial Cells Contributes to Vascular Endothelial Growth Factor Receptor Inhibitor-Induced Vascular and Kidney Damage. American Journal of Hypertension. 2025. doi:10.1093/ajh/hpae140

BibTeX
@article{Camarda2025,
  author = {Camarda, Nicholas D and Lu, Qing and Tesfu, Angelina F and Liu, Rui R and Ibarrola, Jaime and Jaffe, Iris Z},
  title = {Mineralocorticoid Receptor in Endothelial Cells Contributes to Vascular Endothelial Growth Factor Receptor Inhibitor-Induced Vascular and Kidney Damage},
  journal = {American Journal of Hypertension},
  year = {2025},
  doi = {10.1093/ajh/hpae140}
}
Kostenlos starten →